

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014 PC

DESPATCHED ON 16TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B7, B51; Cw7, Cw15; DR15, DR4; DQ6, DQ7

Summary of Results					Summary of Results				
Total tested	26	26	26	26	20	21	21	21	
Positive	13	1	9	0	8	0	1	0	
Negative	13	25	17	26	12	21	20	21	
Not Tested / Equivocal	1	1	1	1	1	1	1	1	
% Positive	50.0%	3.8%	34.6%	0.0%	40.0%	0.0%	4.8%	0.0%	
% Negative	50.0%	96.2%	65.4%	100.0%	60.0%	100.0%	95.2%	100.0%	
Consensus	Not Assessed	Negative	Not Assessed	Negative	Not Assessed	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	Bw6	DQ3	DR7,DQ2	A32,B44,DR7					
Lab No.	Serum 1	Without DTT			With DTT (Not assessed)				Comments
		Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
116	Positive	Positive	Positive	Negative	Positive	Negative	Positive	Negative	
119	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
120	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
128	Negative	Negative	Negative	Negative					
139	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
143	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
147	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
149	Positive	Negative	Positive	Negative					
154	Negative	Negative	Negative	Negative					
159	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
174	Uninterpretable	Uninterpretable	Uninterpretable	Uninterpretable	Uninterpretable	Uninterpretable	Uninterpretable	Uninterpretable	Extensive background lysis and cell death
181	Positive	Negative	Positive	Negative					
189	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
190	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
193	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
194	Weak Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
195	NT	NT	NT	NT	NT	NT	NT	NT	Late delivery of the samples - No cells
197	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
209	Positive	Negative	Negative	Negative	Uninterpretable	Negative	Negative	Negative	
216	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
229	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
232	Positive	Negative	Positive	Negative					
238	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	
260	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	Negative	Negative	Weak Positive	Negative	Negative	Negative	Negative	Negative	
297	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
315	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014 PC

DESPATCHED ON 16TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells	
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'		
112	6	1	4	1	6	1	1	1	23-Sep	24-Sep	Yes		No	90		Cedarlane	30	60	Stain Fix
116	6	6	4	1	6	1	2	1	17-Sep	18-Sep		Yes	No	90	90	Cedarlane	20	60	EB/AO
119	6	1	2	1	2	1	1	1	18-Sep	18-Sep	Yes		No	95		BioRad	30	60	Eosin
120	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes	100		Servibio	30	60	EB/AO
128	1	1	1	1					17-Sep	19-Sep	Yes		No	98		One Lambda	45	90	Stain Fix
139	6	1	1	1	4	1	1	1	18-Sep	19-Sep	Yes	Yes	Yes	90	90	Cedarlane	30	60	Eosin
143	2	1	1	1	1	1	1	1	18-Sep	19-Sep		Yes	Yes	95	95	Cedarlane	30	60	Eosin
147	6	1	1	1	6	1	1	1	17-Sep	17-Sep		Yes	Yes	100		In-House	30	60	Fluoroquench
149	6		2-4						17-Sep	18-Sep	Yes			90			60	60	Eosin
154	1	1	1	1					17-Sep	18-Sep		Yes	No	95	95	Cedarlane	30	60	Eosin
159	6	1	1	1	8	1	1	1	17-Sep	18-Sep		Yes	Yes	90		In-House	30	60	Fluoroquench
174									22-Sep	22-Sep	Yes		No						
181	4	1	4	1					17-Sep	17-Sep	Yes			100		Cedarlane	30	45	EB
189	1	1	1	1	1	1	1	1	18-Sep	18-Sep	Yes		No	86		BioRad	40	40	EB/AO
190	3%	3%	3%	3%	3%	3%	3%	3%	17-Sep	17-Sep		Yes	Yes	95		Cedarlane	30	60	Fluoroquench
193	6	1	4	1	8	1	1	1	17-Sep	17-Sep		Yes	No	99		Cedarlane	30	60	Stain Fix
194	4	1	1	1	2	1	1	1	17-Sep	18-Sep		Yes	Yes	100		In-House	30	45	Fluoroquench
195	NT	NT	NT	NT	NT	NT	NT	NT	01-Oct	NT	NT	NT	NT	0	0	NT	NT	NT	NT
197									17-Sep	18-Sep		Yes	Yes	90	90	One Lambda	30	60	Fluoroquench
209	4								17-Sep	18-Sep	Yes		No	90		Ingen	30	60	Fluoroquench
216	4	2	2	2	4	2	2	2	18-Sep	19-Sep	Yes		No	90		BioRad	30	60	PI
229	100	100	100	100	100	100	100	100	18-Sep	18-Sep	Yes		No	70		Cedarlane	30	60	EB/AO
232	4+		4+						18-Sep	19-Sep			No	80		Biotest	45	60	EB/AO
238	1	1	2	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes	95		Invitrogen	45	90	Fluoroquench
260									18-Sep	18-Sep		Yes	Yes	85		Innotrain	30	60	EB/AO
262	1	1	4	1	1	1	1	1	17-Sep	17-Sep	Yes	Yes	Yes	100	100	Invitrogen	30	60	Eosin
297	2	1	1	1	2	1	1	1	17-Sep	18-Sep	Yes	Yes	Yes	90		Cedarlane	30	60	Fluoroquench
315	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes	80		Servibio	30	50	Fluoroquench

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014 PC

DESPATCHED ON 16TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B7, B51; Cw7, Cw15; DR15, DR4; DQ6, DQ7

Summary of Results					Summary of Results				
Total tested	15	15	15	15	13	13	13	13	
Positive	11	6	14	0	9	4	3	0	
Negative	4	9	1	15	4	9	10	13	
Not Tested / Equivocal	2	2	2	2	2	2	2	2	
% Positive	73.3%	40.0%	93.3%	0.0%	69.2%	30.8%	23.1%	0.0%	
% Negative	26.7%	60.0%	6.7%	100.0%	30.8%	69.2%	76.9%	100.0%	
Consensus	Not Assessed	Not Assessed	Positive	Negative	Not Assessed	Not Assessed	Negative	Negative	
HLA Antibody (Defined By CDC)	Bw6	DQ3	DR7,DQ2	A32,B44,DR7					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
120	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	
139	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
147	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
154	Positive	Negative	Negative	Negative					
159	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
181	Positive	Positive	Positive	Negative					
190	NT	NT	NT	NT	NT	NT	NT	NT	Few cells. 60% mortality
193	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
194	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
195	NT	NT	NT	NT	NT	NT	NT	NT	Late delivery of the samples - No cells
197	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
209	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	
238	Negative	Positive	Positive	Negative	Negative	Positive	Negative	Negative	
260	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
262	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative	
297	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
315	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014 PC

DESPATCHED ON 16TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
120	1	1	8	1	1	1	1	1	17-Sep	18-Sep		60	Servibio	30	60	EB/AO
139	8	4	6	1	8	4	1	1	18-Sep	19-Sep	Yes	90	Cedarlane	30	60	Eosin
147	6	1	6	1	6	1	1	1	17-Sep	17-Sep	Yes	100	In-House	30	60	Fluoroquench
154	2	1	1	1					17-Sep	18-Sep	No	70	Cedarlane			Stain Fix
159	8	1	4	1	8	1	1	1	17-Sep	18-Sep	Yes	50	In-House	30	60	Fluoroquench
181	4	4	6	1					17-Sep	17-Sep	Yes	100	Cedarlane	30	45	EB
190	NT	NT	NT	NT	NT	NT	NT	NT	17-Sep	17-Sep	Yes	40	Cedarlane	30	60	Fluoroquench
193	4	1	8	1	6	1	1	1	17-Sep	17-Sep	Yes	98	Cedarlane	30	60	Hb/PI
194	8	1	6	1	4	1	1	1	17-Sep	18-Sep	Yes	100	In-House	30	45	Fluoroquench
195	NT	NT	NT	NT	NT	NT	NT	NT	01-Oct	NT	NT	0	NT	NT	NT	NT
197									17-Sep	18-Sep	Yes	90	One Lambda	30	60	Fluoroquench
209	8	4	2		4				17-Sep	18-Sep	Yes	90	Ingen			Fluoroquench
238	1	2	4	1	1	2	1	1	17-Mar	18-Sep	Yes	90	Invitrogen	45	90	Fluoroquench
260			++++				++++		18-Sep	18-Sep	Yes	85	Innotrain	30	60	EB/AO
262	8	6	8	1	8	6	8	1	17-Sep	17-Sep	Yes	100	Invitrogen	60	90	Eosin
297	4	1	6	1	4	1	1	1	17-Sep	18-Sep	Yes	90	Cedarlane	30	60	Fluoroquench
315	6	1	6	1	6	1	1	1	17-Sep	18-Sep	Yes	80	Servibio	30	50	Fluoroquench

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate